Creative Medical Technology
CELZ
17 hedge funds and large institutions have $258K invested in Creative Medical Technology in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
21% more funds holding
Funds holding: 14 → 17 (+3)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
1.96% less ownership
Funds ownership: 2.38% → 0.42% (-2%)
77% less capital invested
Capital invested by funds: $1.13M → $258K (-$874K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$175K |
| 2 |
VF
Virtu Financial
New York
|
+$37K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$7.31K |
| 4 |
Millennium Management
New York
|
+$6.8K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$4.78K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$933K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$9.33K |
| 3 |
Citigroup
New York
|
-$5K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$41 |
CELZ Hedge Fund Activity: Q3 2022 in Review
17 of the 5,827 institutional investors tracked by Wall St. Rank reported a position in Creative Medical Technology (CELZ) for Q3 2022, worth a combined $258K — down 77% from $1.13M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CELZ positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $175K. The largest seller was Armistice Capital, exiting entirely with an estimated $933K sold.
- 17 institutional investors held Creative Medical Technology (CELZ) as of Q3 2022, up from 14 in Q2 2022.
- Funds reported $258K of Creative Medical Technology stock for Q3 2022, down 77% quarter-over-quarter.
- 5 funds opened new Creative Medical Technology positions in Q3 2022 and 2 closed out, a net change of +3 holders.
- The largest Creative Medical Technology buyer in Q3 2022 was Citadel Advisors, an estimated $175K added.
- The largest Creative Medical Technology seller in Q3 2022 was Armistice Capital, an estimated $933K sold.
Based on aggregated 13F filings for Q3 2022.